Navigation Links
Diabetics Need to Guard Against Nail Fungus

Many people with diabetes have nail fungus, which can have a serious impact on their health and quality of life. The American Association of Diabetes Educators (AADE) says about a third of the estimated Americans who have diabetes develop onychomycosis, the most common type of nail fungus. Because of poor circulation in the extremities and a reduced ability to fight infection, people with diabetes are at greater risk for nail fungus.//
For people with diabetes, nail fungus may start out as an embarrassment. But if left untreated, nail fungus can progress to skin and bone infections or even tissue death, leading to a loss of mobility and independence. Symptoms of nail fungus include changes in the color, texture and thickness of the nail. The nail may be easily broken and the toenail may thicken and cause pressure, especially when shoes are worn. People with nail fungus may have trouble walking or wearing shoes. The infection can spread to other nails and other people.

Now that the warm weather is here, people with diabetes may be at greater risk of developing nail fungus. That's because they're more exposed to specific risk factors such as walking barefoot in swimming pools, communal showers and other areas potentially contaminated with nail fungus.

The AADE offers these tips on preventing nail fungus:
Don't wear tight-fitting shoes or the same pair of shoes every day.
Wear socks that absorb moisture.
Wash and dry feet daily.
Remove shoes and socks at every doctor visit so you feet can be examined.
Treatment for nail fungus may include oral or topical antifungal agents.

'"/>




Page: 1

Related medicine news :

1. Cinnamon May Help Diabetics
2. Heart disease threat starts early in life for Diabetics
3. Diabetics and their babies
4. Beta-Carotene May Aid Diabetics
5. Diabetics prone to periodontitis
6. Blood Vessel Surgery Safe for Diabetics
7. Marriage does good for Diabetics
8. Niacin Safe for Diabetics
9. Diabetics & Foot infections
10. Pancreas Transplant for Diabetics
11. Poor Preventive Measures Taken By Diabetics
Post Your Comments:
(Date:5/16/2008)...ed for May 19 at 10:15 a.m. Eastern Time, VANCOUV...dical,Corporation (TSX: RBM, OTCBB: RPBIF) today a...r, is scheduled to present at the Rodman & Renshaw... May 19th at 10:15 a.m.,EDT., A live web cast of ...s,Web site at, http://www.responsebio.com/newsroom...
(Date:5/16/2008).../PRNewswire-USNewswire/ -- Emergency Medical,Servi...ght the dedication,of Pennsylvania,s first respond...EMS volunteers, according to state Secretary of He...: Your Life is Our Mission," emphasizes that no,ma...is there to provide,immediate, life-saving care an...
(Date:5/16/2008)...th Drops More in 2007, WASHINGTON, May 16 /PRNews...n three cancer deaths, the National Cancer Institu... budget in lung cancer research in 2007,according...nce (LCA) today., The two other federal agencies ...rs for Disease Control and Prevention (CDC) and th...
(Date:5/16/2008)... disseminated to community physicians, audit finds...Partnerships between major academic cancer centers... way to spread cancer treatment advances, say rese.... , Most new cancer treatments are created at m...ided at community hospitals, noted the researchers...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:Partnerships Effective Communicators of Cancer Advances 2
...rs in New Zealand have warned against using tradit...ed lead poisoning using them, it was reported Frid... substantial threat to well-being posed by a parti...urvedic medicine," doctors said in a report in the...
...hinese soybean lines that grow without the primary...dults have been isolated by scientists//. The two ...ons and will be given away to breeders seeking to ...lergy-free soybeans without genetic engineering. ...
...mittee of MPs have termed the shake-up of the out ...ic" that only led to longer waits and higher costs...e new health care providers are spending 22% more ...ny key targets. In 2004 most GPs had opted out of...
...ar-old girl, Stephanie Mullen, a type 1 diabetic h...that the girl could have probably run out of medic...led for public attention in this matter. Stephani...nday. Stephanie went missing after spending Monday...
Other Medicine News:Health News:Promise for Soya Allergy Sufferers 2
(Date:5/15/2008)... Patients with breast or,colorectal cancer, two of...er treatment advances with Avastin(R) (bevacizumab...a that is being presented at the 44th,American Soc... Chicago at,the end of May. Around 30,000 medical ...er event for cancer therapy worldwide., The Roche...
(Date:5/15/2008)...tate, Colorectal and Ovarian ...ent on Sun., June 1 with Oncology Experts -, SOUT...all/ -- Poniard,Pharmaceuticals, Inc. (Nasdaq: PA...ogy, today announced that the Company will present... various tumor types and combinations, at,poster s...
(Date:5/15/2008)...cts depth and breadth of, collaboration with inve... diverse forms of cancer -... the leading IV, bisphosphonate, on relapse rate o... oral sessions to feature RAD001, first oral once-...st results of RECORD-1 study in renal cell ...
(Date:5/15/2008)...tCall/ -- Sanofi-aventis,(EURONEXT: SAN and NYSE: ...rk ATHENA study showed Multaq(R) (dronedarone), a ...th atrial fibrillation or atrial flutter,decrease...eath from any,cause by a statistically significant...point. The ATHENA results will be presented at the...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Coalition America Renews Relationship with Musketeer to Offer Streamlined Claims Repricing and Adjudication Solution for Benefit Administrators 1971 1Coalition America Renews Relationship with Musketeer to Offer Streamlined Claims Repricing and Adjudication Solution for Benefit Administrators 1971 2Race Against Pain Coming to California 1968 1Race Against Pain Coming to California 1968 2Race Against Pain Coming to California 1968 3Portico Systems Wins Three Awards in 30 Days 1965 1Portico Systems Wins Three Awards in 30 Days 1965 2Signalife Receives Another 243 3 Million Sales Orders 813 1Signalife Receives Another 243 3 Million Sales Orders 813 2
...nd VANCOUVER, April 26, 2007,/PRNewswire-FirstCall...cialty pharmaceutical and medical device company, ... pivotal trial examining the,Vascular Wrap(TM) Pac... presented today at a scientific forum in Europe. ...y of the Vascular,Wrap(TM) for use in arterial byp...
...pril 26, 2007 /PRNewswire-FirstCall/ --,Australian...nnounced preliminary results from its randomised P... colorectal cancer, where,Alchemia,s drug HyCAMP(T...to be a cornerstone drug for the treatment of colo...a preliminary stage of,the analysis in accordance ...
Other Medicine Technology:Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 2Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 3Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 4Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 5Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 6Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial 7
Toothed Pituitary Rongeurs, 12 300 mm.
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation.
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse.
It is designed to give rigid skeletal fixation, which allows surgeons more freedom in positioning fixation pins. It provides 3-point rigid skeletal fixation for the supine, prone, lateral, or sitting
Medicine Products: